title: Comparison of oral alendronate versus prednisolone in treatment of infants with vitamin D intoxication.
abstract: OBJECTIVE
  The aim of this report was to compare the efficacy of oral alendronate versus prednisolone treatment in addition to conventional measures in infants with vitamin D intoxication.
  
  
  METHODS
  In six infants (aged 8.0 ± 2.1 months) with vitamin D intoxication, time to achieve normocalcemia with prednisolone treatment (Group I, n = 4) or alendronate treatment (Group II, n = 4, two infants started treatment from the baseline and two after unsuccessful prednisolone treatment) in addition to intravenous hydration and diuretic therapy were compared.
  
  
  RESULTS
  Baseline serum calcium levels ranged between 3.8 and 4.77 mmol/L. In the prednisolone group, although two patients reached normocalcemia on 7th and 12th days of treatment, other two patients did not despite 23 and 15 days of treatment and therefore switched to alendronate treatment. The mean duration of prednisolone treatment in these four patients was 14.2 ± 6.7 days (range 7-23). In the alendronate group, two patients who started treatment from the baseline achieved normocalcemia on the 5th day. Other two patients achieved normocalcemia 2 days after switching to alendronate. Thus, the mean time to reach normocalcemia after single oral alendronate administration was 3.5 ± 1.7 days (range 2-5) (p < 0.01 versus Group I).
  
  
  CONCLUSIONS
  Alendronate treatment achieves normocalcemia four times earlier than prednisolone treatment and shortens hospital stay in infants with vitamin D intoxication.
authors: Department of Pediatrics, Zeynep Kamil Maternity and Childrens Diseases Research and Training State Hospital, Istanbul, Turkey. rabiagonul@hotmail.com
authors: Rabia G
authors: RG
authors: Sezer
authors: Tulay
authors: T
authors: Guran
authors: Cem
authors: C
authors: Paketçi
authors: Lale P
authors: LP
authors: Seren
authors: Abdulkadir
authors: A
authors: Bozaykut
authors: Abdullah
authors: A
authors: Bereket
mesh_terms: D000284:Administration, Oral; D019386:Alendronate / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D062787:Drug Overdose / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D007223:Infant; D007902:Length of Stay; D011239:Prednisolone / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014807:Vitamin D / Q000506:poisoning*
chemical_list: D000893:Anti-Inflammatory Agents; D050071:Bone Density Conservation Agents; D014807:Vitamin D; D011239:Prednisolone; D019386:Alendronate